Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Immunology
Fator do impacto: 1.352 FI de cinco anos: 3.347 SJR: 1.022 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472

Volumes:
Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.2013008033
pages 489-547

Therapeutic Dendritic Cell−Based Cancer Vaccines: The State of the Art

Marius M. Strioga
Department of Immunology, Center of Oncosurgery, Institute of Oncology, Vilnius University, Vilnius, Lithuania
Thomas Felzmann
Activartis Biotech GmbH, Vienna; Laboratory of Tumor Immunology, St. Anna Children's Cancer Research Institute, Vienna, Austria
Daniel J. Powell Jr.
Ovarian Cancer Research Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Valerijus Ostapenko
Sector of Breast surgery, Third Department of Oncosurgery, Center of Oncosurgery, Institute of Oncology, Vilnius University, Vilnius, Lithuania
Neringa T. Dobrovolskiene
Department of Immunology, Center of Oncosurgery, Institute of Oncology, Vilnius University, Vilnius, Lithuania; Department of Immunology, State Research Institute Center for Innovative Medicine, Vilnius, Lithuania
Miroslava Matuskova
Laboratory of Molecular Oncology, Cancer Research Institute, Slovak Academy of Sciences, Bratislava, Slovakia
Jaroslav Michalek
Advanced Cell Immunotherapy Unit, Department of Pharmacology, Medical Faculty, Masaryk University, Brno; Cellthera Ltd., Brno, Czech Republic
Virgil E. J. C. Schijns
Immune Intervention, Cell Biology & Immunology group, Wageningen University, Wageningen, the Netherlands; Epitopoietic Research Corporation, Namur, Belgium

RESUMO

Dendritic cells (DCs) are the most potent professional antigen-presenting cells, capable of initiating proper adaptive immune responses. Although tumor-infiltrating DCs are able to recognize cancer cells and uptake tumor antigens, they often have impaired functions because of the immunosuppressive tumor milieu. Therefore, DCs are targeted by therapeutic means either in vivo or ex vivo to facilitate tumor antigen presentation to T cells and induce or promote efficient antitumor immune responses in cancer patients. This immunotherapeutical approach is defined as specific active tumor immunotherapy or therapeutic cancer vaccination. In this review we briefly discuss general aspects of DC biology, followed by a thorough description of the current knowledge and optimization trends of DC vaccine production ex vivo, including various approaches for the induction of proper DC maturation and efficient loading with tumor antigens. We also discuss critical clinical aspects of DC vaccine application in cancer patients, including protocols of administration (routes and regimens), individualization of tumor immunotherapy, prediction and proper evaluation of immune and clinical responses to immunotherapy, and the critical role of combining tumor immunotherapy with other cancer treatment strategies to achieve maximal therapeutic effects.


Articles with similar content:

Dendritic Cells in Cancer Immunotherapy
Critical Reviews™ in Immunology, Vol.21, 2001, issue 1-3
Matthias Gunzer, Stephan Grabbe
IL-21 Is an Immune Activator That also Mediates Suppression via IL-10
Critical Reviews™ in Immunology, Vol.30, 2010, issue 6
Warren J. Leonard, Rosanne Spolski
The Phenotype and Function of Lung Dendritic Cells
Critical Reviews™ in Immunology, Vol.25, 2005, issue 6
Allison T. Thiele, Kena A. Swanson, Tina L. Sumpter, Tonya J. Webb, David S. Wilkes
Autophagy and Autophagy-Related Proteins in the Immunity against Mycobacterium Tuberculosis
Forum on Immunopathological Diseases and Therapeutics, Vol.6, 2015, issue 3-4
Isabelle Vergne, Aïcha Bah
Immune-Mediated Oligodendrocyte Injury in Multiple Sclerosis: Molecular Mechanisms and Therapeutic Interventions
Critical Reviews™ in Immunology, Vol.22, 2002, issue 5-6
Piet Stinissen, Marcel Ameloot, Mieke Buntinx, Jef Raus, Paul Steels